Citations Appearing in 2006

  1. Alexandre, J., E. Rey, V. Girre, S. Grabar, A. Tran, V. Montheil, F. Rabillon, V. Dieras, V. Jullien, P. Herait, G. Pons, J.M. Treluyer and F. Goldwasser. Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Annals of Oncology 18(1):168-172, 2006.
  2. Anderson, B.J., K. Allegaert and N.H.G. Holford. Population clinical pharmacology of children: general principles. European Journal of Pediatrics 165(11):741-746, 2006.
  3. Aumente, D., D. Santos Buelga,J.C. Lukas, P. Gomez, A. Torres, M.J. Garcia. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clinical Pharmacokinetics 45(12):1227-1238, 2006.
  4. Best, B.M., M. Mirochnick, E.V. Capparelli, A. Stek, S.K. Burchett, D.T. Holland, J.S. Read, E. Smith, C.C. Hu, S.A. Spector and J.D. Connor. Impact of pregnancy on abacavir pharmacokinetics. AIDS 20(4):553-560, 2006.
  5. Bhasi, K., A. Forrest, and M. Ramanathan. Application of SPLINDID, a semiparametric, model-based method for pharmacogenomic modeling of mRNA dynamics. Pharmaceutical Research 23(4):663-669, 2006.
  6. Beumer, J.H., E. Joseph, M.J. Egorin, R.S. Parker, D.Z. D’Argenio, J.M. Covey and J.L. Eiseman. A mass balance and disposition study of the DNA methyltransferase inhibitor zebularine (NSC 309132) and three of its metabolites in mice. Clinical Cancer Research 12(19):5826-5833, 2006.
  7. Boak, L.M., J. Li, D. Spelman, P. Cros, R.L. Nation and C.R. Rayner. Successful treatment and cerebrospinal fluid penetration of oral linezolid in a patient with coagulase-negative Staphylococcus ventriculitis. The Annals of Pharmacotherapy40(7):1451-1455, 2006.
  8. Bullock, J.M., P.F. Smith, B.M. Booker, J. Loughner, D. Capozzi, P.L. McCarthy and L.M. Shaw. Development of a pharmacokinetic and Bayesian optima sampling model for individualization of oral busulfan in hematopoietic stem cell transplantation. Therapeutic Drug Monitoring 28(1):62-66, 2006.
  9. Chen, M., A.N. Nafziger, G.L. Drusano, L. Ma, and J.S. Bertino. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimibrobial Agents and Chemotherapy 50(4):1222-1227, 2006.
  10. Chintagumpala, M.M., H.S. Friedman, C.F. Stewart, J. Kepner, R.E. McLendon, P.L. Modrich, C. McCluggage, P. Burger, E. Holmes, S. Thompson, J. Rutka, J. Michalski, S. Woo, S.M. Blaney, L.E. Kun and M.E. Horowitz and A Pediatric Oncology Group Study. A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children’s oncology group. Journal of Neuro-Oncology 77(2):193-198, 2006.
  11. del Castillo, J.R., V. Laroute, P. Pommier, C. Zemirline, A. Keita, D. Concordet and P.L. Toutain. Interindividual variability in plasma concentrations after systemic exposure of swine to dietary doxycycline supplied with and without paracetamol: a population pharmacokinetic approach. Journal of Animal Science 84(11):3155-3166, 2006.
  12. Dutta, S. and R.C. Reed. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician. Journal of Clinical Pharmacy and Therapeutics 31(4):321, 2006.
  13. Feng, Y. Modeling and simulation approach to characterize the magnitude and consistency of drug exposure using sparse concentration sampling. (Doctoral dissertation, University of Pittsburgh), 2006.
  14. Fouladi, M., W.L. Furman, T. Chin, B.B. Freeman III, L. Dudkin, C.F. Stewart, M.D. Krailo, R. Speights, A.M. Ingle, P.J. Houghton, J. Wright, P.C. Adamson and S.M. Blaney. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a children’s oncology group report. Journal of Clinical Oncology 24(22):3678-3685, 2006.
  15. Freeman, B.B III, L.C. Iacono, J.C. Panetta, A. Gajjar and C.F. Stewart. Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma. Neuro-Oncology 8(2):89-95, 2006.
  16. Furman, W.L., K.R. Crews, C. Billups, J.R. Wu, A.J. Gajjar, N.C. Daw, C.C. Patrick, C. Rodriguez-Galindo, C.F. Stewart, J.S. Dome, J.C. Panetta, P.J. Houghton and V.M. Santana. Cefixime allows greater dose escalation of oral irinotecan: A phase I study in pediatric patients with refractory solid tumors. Journal of Clinical Oncology 24(4):563-570, 2006.
  17. Graham, C., C. Tucker, J. Creech, E. Favours, C.A. Billups, T.B. Liu, M. Fouladi, B.B. Freeman, C.F. Stewart and P.J. Houghton. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clinical Cancer Research 12(1):223-234, 2006.
  18. Gumbo, T., G.L. Drusano, W. Liu, L. Ma, M.R. Deziel, M.F. Drusano and A. Louie. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrobial Agents and Chemotherapy 50(11):3695-3700, 2006.
  19. Gupta, P., A. A. Miller, K. Owzar, D. J. Murry, B. L. Sanford, R. Vij, D. Yu, R. P. Hasserjian, R. A. Larson and M. J. Ratain. Pharmacokinetics of an oral VEGF receptor tyrosine kinase inhibitor (PTK787/ZK222584) in patients with myelodysplastic syndrome (MDS): Cancer and Leukemia Group B Study 10105. Journal of Clinical Oncology 24(18S):6573, 2006.
  20. Han, E.E., P.M. Beringer, P. Falck, S. Louie, P. Rao, B. Shapiro and M. Gill. Pilot study of continuous infusion cefepime in adult patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy Advance Access 57(5):1017, 2006.
  21. Hazra, A., W. Krzyzanski and W.J. Jusko. Mathematical assessment of properties of precursor-dependentindirect pharmacodynamic response models. Journal of Pharmacokinetics and Pharmacodynamics 33(6):683-717, 2006.
  22. Herrington, J.D., H.T. Tran and M.W. Riggs. Prospective evaluation of carboplatin AUC dosing in patients with a BMI=<27 or Cachexia. Cancer Chemotherapy and Pharmacology 57(2):241-247, 2006.
  23. Hon, Y.Y., W.J. Jusko, V.E. Spratlin and M.W. Jann. Altered methylprednisolone pharmacodynamics in healthy subjects with histamine n-methyltransferase C314T genetic polymorphism. Journal of Clinical Pharmacology 46(4):408-417, 2006.
  24. Hope, W.W., P.A. Warn, A. Sharp, S. Howard, M. Kasai, A. Louie, T.J. Walsh, G.L. Drusano, D.W. Denning. Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect. Antimicrobial Agents and Chemotherapy 50(11):3680-3688, 2006.
  25. Horton, T.M., A. Gannavarapu, S.M. Blaney, D.Z. D’Argenio, S.E. Plon and S.L. Berg. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemotherapy and Pharmacology 58(1):13-23, 2006.
  26. Jamal, N.M., W. Kyzyzanski, W. Cheung, C.Y. Lae and H.A. Messner. Evaluation of epoetin alpha (rHuEPO) and darbepoetin alpha (DARB) on human burst-colony formation (BFU-E) in culture. Cancer Chemotherapy and Pharmacology 57(1):15-24, 2006.
  27. Jumbe, N.L., A. Louie, M.H. Miller, W.G. Liu, M.R. Deziel, V.H. Tam, R. Bachhawat and G.L. Drusano. Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 50(1):310-317, 2006.
  28. Kirstein, M.N., R.C. Brundage, W.F. Elmquist, R.P. Remmel, P.H Marker, D.E. Guire and D. Yee. Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens. Breast Cancer Research and Treatment 96(3):217-225, 2006.
  29. Krzyzanski, W., J. Dmochowski, N. Matsushima, and W.J. Jusko. Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models. Journal of Pharmacokinetics and Pharmacodynamics 33(5):635-655, 2006.
  30. Krzyzanski, W., S. Woo and W.J. Jusko. Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans. Journal of Pharmacokinetics and Pharmacodynamics 33(2):125-166, 2006.
  31. Kurup, A., C.W. Lin, D.J. Murry, L. Dobrolecki, D. Estes, C.T. Yiannoutsos, L. Mariano, C. Sidor, R. Hickey and N. Hanna. Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. Annals of Oncology 17(1):97-103, 2006.
  32. Lodise,T.P., L. Ma, R. Pypstra, J. Kahn, G.L. Drusano and G.L. Noel. Pharmacodynamic profiling of ceftobiprole for the treatment of complicated skin and skin structure infections and nosocomial pneumonia. Clinical Microbiology and Infection 12(s4):1524, 2006.
  33. Mattison, L., E. Acosta, J. Fourie and R. Diasio. Describing the catabolism of orally administered 2-13C-uracil in normal and dihydropyrimidine dehydrogenase deficient subjects using a parent/metabolite/breath model: LBOVI-B-2. Clinical Pharmacology and Therapeutics 79(2):P83-P83, 2006.
  34. Meno-Tetang G.M., H. Li, S. Mis, N. Pyszczynski, P. Heining, P. Lowe and W.J. Jusko. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metabolism and Disposition 34(9):1480-1487, 2006.
  35. Messersmith W.A., S.D. Baker, L. Lassiter, R.A. Sullivan, K. Dinh, V.I. Almuete, J.J. Wright, R.C. Donehower, M.A. Carducci and D.K. Armstrong. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clinical Cancer Research 12(4):1270-1275, 2006.
  36. Minderman, H., K.L. O’Loughlin, P.F. Smith, L. Pendyala, W.R. Greco, K.G. Sweeney, L.A. Ford, M. Wetzler and M.R. Baer. Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia. Cancer Chemotherapy and Pharmacology 57(1):73-83, 2006.
  37. Ng, C.M., Stefanich, B.S. Anand, P.J. Fielder and L. Vaickus. Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharmaceutical Research 23(1):95-103, 2006.
  38. Panetta, J.C., W.W. Evans and M.H. Cheok. Mechanistic mathematical modelling of mercaptopurine effects on cell cycle of human acute lymphoblastic leukaemia cells. British Journal of Cancer 94(1):93-100, 2006.
  39. Peloquin, C.A., J.N. Maslow, S.K. Mikota, A. FOrrest, F. Dunker, R. Isaza, L.R. Peddie, J. Peddie and M. Zhu. Dose selection and pharmacokinetics of rifampin in elephants for the treatment of tuberculosis. Journal of Veterinary Pharmacology and Therapeutics 29(6):581-585, 2006.
  40. Raje, S., J. Cornish, A.H. Newman, J. Cao, J.L. Katz and N.D. Eddington. Investigation of the potential pharmacokinetic and pharmaco-dynamic drug interaction between AHN 1-055, a potent benztropine analog used for cocaine abuse, and cocaine after dosing in rats using intracerebral microdialysis. Biopharmaceutics and Drug Disposition 27(5):229-240, 2006.
  41. Ramanathan, R.K., M. Fakih, S. Mani, M. Deutsch, R.P. Perez, M.A. Ritter, J.L. Eiseman, S.P. Ivy, D.L. Trump, C.P. Belani, R.A. Parise, D.M. Potter and M.J. Egorin. Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy inpatients with locally advanced pancreatic of bili ary cancers. Cancer Chemotherapy and Pharmacology 57(4):465-474, 2006.
  42. Ribaudo, H.J., D.W. Haas, C. Tierney, R.B. Kim, G.R. Wilkinson, R.M. Gulick, D.B. Clifford, C. Marzolini, C.V. Fletcher, K.T. Tashima, D.R. Kuritzkes and E.P. Acosta. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An adult AIDS clinical trials group study. Clinical Infectious Diseases 42(3):401-407, 2006.
  43. Rodrigues, L.M., P.C. Pinto, J.M. Magro, N. Furtado and M.A. Roberto. Quantitative follow-up of the cutaneous barrier function in wound healing. Exogenous Dermatology 3(6):303-306, 2006.
  44. Rodriguez-Galindo, C., K.R. Crews, C.F. Stewart, W. Furman, J.C. Panetta, N.C. Daw, A. Cain, M. Tan, P.H. Houghton and V.M. Santana. Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. Cancer Chemotherapy and Pharmacology 57(1):15-24, 2006.
  45. Russell, S. and J.J. DiStefano. W3MAMCAT: A world wide web based tool for mammillary and catenary compartmental modeling and expert system distinguishability. Computer Methods and Programs in Biomedicine 83(1):34-42, 2006.
  46. Saint-Marcoux, F, P. Marquet, E. Jacqz-Aigrain, N. Bernard, P. Thiry, Y. Le Meur and A. Rousseau. Patient characteristics influencing ciclosporin pharmacokinetics and accurate bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. Clinical Pharmacokinetics 45(9):905-922, 2006.
  47. Samanti, M.N., N.A. Pyszczynski, D.C. DuBois, R.R. Almon and W.J. Jusko. Modeling glucocorticoid-mediated fetal lung maturation: I. Temporal patterns of corticosteroids in rat pregnancy. Journal of Pharmacology and Experimental Therapeutics 317(1):117-126, 2006.
  48. Shaughnessy, P., W. Alexander, H. Tran, D. Ririe, J. Splichal, M. Pollack, C. Bachier and C. LeMaistre. Phase I and pharmacokinetic study of once-daily dosing of intravenously administered busulfan in the setting of a reduced-intensity preparative regimen and allogeneic hematopoietic stem cell transplantation as immunotherapy for renal cell carcinoma. Diagnostic microbiology and infectious disease 171(2):161-165, 2006.
  49. Sprandel, K.A., G.L. Drusano, D.W. Hecht, J.C. Rotschafer, L.H. Danziger and K.A. Rodvold. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole. Military Medicine 55(4):303-309, 2006.
  50. Tam, V.H., S. Adams, M.T. Larocco, L. N. Gerard, L.O. Gentry and K.W. Garey. An integrated pharmacoeconomic approach to antimicrobial formulary decision-making. American Journal of Health-System Pharmacy 63(8):735-739, 2006.
  51. Tam, V.H. and S. Kabbara. Comparative performance of different stochastic methods to simulate drug exposure and variability in a population. Diagnostic Microbiology and Infectious Disease 56(2):185-188, 2006.
  52. Tam, V.H., S. Kabbara, G. Vo, A.N. Schilling, and E.A. Coyle. Comparative pharmacodynamics of gentamicin against staphylococcus aureus and pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 50(8):2626-2631, 2006.
  53. Tham, L.S., H.S. Lee, L.Z. Wang, W.P. Yong, L. Fan, A.B. Ong, N. Sukri, R. Soo, S.C. Lee and B.C. Goh. Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug. Therapeutic Drug Monitoring 28(2):255-261, 2006.
  54. Ting, L.S.L., E. Villenueve and M.H.H. Ensom. Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Therapeutic Drug Monitoring 28(3):419-430, 2006.
  55. Tran, A., V. Jullien, J. Alexandre, E. Rey, F. Rabillon, V. Girre, V. Dieras, G. Pons, F. Goldwasser and J. Tréluyer. Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms. Clinical Pharmacology and Therapeutics 79(6):570-580, 2006.
  56. Turner, P.K., L.C. Iacono, J.C. Panetta, V.M. Santana, N.C. Daw, A. Gajjar and C.F. Stewart. Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children. Cancer Chemotherapy and Pharmacology 57(4):475-482, 2006.
  57. Wang S.W., J. Chen, X. Jia, V.H. Tam and M. Hu. Disposition of flavonoids via enteric recycling: structural effects and lack of correlations between in vitro and in situ metabolic properties. Drug Metabolism and Disposition 34(11):1837-1848, 2006.
  58. Wiederhold, N.P., V.H. Tam, J. Chi, R.A. Prince, D.P. Kontoyiannis and R.E. Lewis. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy 50(2):469-473, 2006.
  59. Woloszczuk-Gebicka, B., E. Wyska, T. Grabowski, A. S’Wierczewska and R. Sawicka. Pharmacokinetic-pharmacodynamic relationship of rocuronium under stable nitrous oxide-fentanyl or nitrous oxide-sevoflurane anesthesia in children. Paediatric Anaesthesia 16(7):761-768, 2006.
  60. Woo, S., W. Krzyzanski and W.J. Jusko. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats. Journal of Pharmacology and Experimental Therapeutics 319(3):1297-1306, 2006.
  61. Yao, Z.L., D.C. DuBois, R.R. Almo and W.J. Jusko. Modeling circadian rhythms of glucocorticoid receptor and glutamine synthetase expression in rat skeletal muscle. Pharmaceutical Research 23(4):670-679, 2006.
  62. Yao, Z.L., W. Krzyzanski and W.J. Jusko. Assessment of basic indirect pharmacodynamic response models with physiological limits. Journal of Pharmacokinetics and Pharmacodynamics 33(2):167-193, 2006.
  63. Yue, Y.C., J. Lavigne, J. Marier, M. Ducharme, L. Pope, J. Berg, T. Brandt and M. Di Marco. Population pharmacokinetic analysis of AVP-923 (30 mg dextromethorphan and 30 mg quinidine): PII-59. Clinical Pharmacology and Therapeutics 79(2):P51-P51, 2006.
  64. Yun, H., E.J. Lee, S.Y. Chung, S. Choi, H.K. Kim, J. Kwon, W. Kang and K. Kwon. The effects of food on the bioavailability of fenofibrate administered orally in healthy volunteers via sustained-release capsule. Clinical Pharmacokinetics 45(4):425-432, 2006.
  65. Yun, H., H. Park, W. Kang and K. Kwon. Pharmacokinetic and pharmacodynamic modelling of the effects of glimepiride on insulin secretion and glucose lowering in healthy humans. Journal of Clinical Pharmacy and Therapeutics 31(5):469-476, 2006.
  66. Zamboni, W.C., S. Goel, T. Iqbal, R.A. Parise, S. Strychor, T.V.W. Repinski, M.J. Egorin and S. Mani. Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors. Cancer Chemotherapy and Pharmacology 57(5):631-639, 2006.
  67. Zhang, X., B.R. Overholser, M.B. Kays and K.M. Sowinski. Gatifloxacin pharmacokinetics in healthy men and women. Journal of Clinical Pharmacology 46(10):1154-1162, 2006.
  68. Zhuang, Y., C.H. Fraga, K.E. Hubbard, N. Hagedorn, J.C. Panetta, C.M. Waters and C.F. Stewart. Topotecan central nervous system penetration is altered by a tyrosinekinase inhibitor. Cancer Research 66(23):11305-11313, 2006.